Article thumbnail

Activity-Based Profiling for Drug Discovery

By Remigiusz Serwa and Edward W. Tate

Abstract

Activity-based protein profiling (ABPP) is emerging as a game-changing tool for drug discovery, target validation, and basic biology. In this issue, Chang et al. (2011) report the ABPP-facilitated discovery of JW480, a highly selective potent and orally bioavailable inhibitor of monoalkylglycerol ether hydrolase KIAA1363 that dramatically impairs in vivo growth of human prostate cancer cell lines

Publisher: Elsevier Ltd.
Year: 2011
DOI identifier: 10.1016/j.chembiol.2011.04.002
OAI identifier:

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.